NCT05219734View on ClinicalTrials.gov

MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment

Active, not recruitingOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

November 29, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
CancerSolid TumorNon Small Cell Lung CancerColorectal CancerBladder Cancer
Interventions
DIAGNOSTIC_TEST

Personalized Cancer Monitoring (PCM)

personalized molecular test for solid tumor cancer patients that may detect the presence of circulating tumor DNA (ctDNA) and molecular residual disease (MRD), also known as minimal residual disease

Trial Locations (2)

28546

Onslow Radiation, Jacksonville

47201

Columbus Regional Health, Columbus

Sponsors
All Listed Sponsors
lead

Invitae Corporation

INDUSTRY